

Supplementary Table S1.

Patient ID	SJC 66	TJC 68	CRP	PP	PtGA	DAPSA	cDAPSA	Expert classification (% of experts)				Majority rating	Percentile rating
								REM	LDA	MDA	HDA		
1	14	23	0.37	28	54	45.57	45.20	3.2	-	9.7	87.1	HDA	HDA
2	4	11	5.54	80	80	36.54	31.00	-	3.3	33.3	63.3	HDA	
3	5	7	0.70	81	75	28.30	27.60	-	6.5	41.9	51.6	HDA	
4	7	15	0.17	46	67	33.47	33.30	-	3.4	41.4	55.2	HDA	
5	9	12	0.99	94	100	41.39	40.40	-	-	-	100	HDA	
6	1	23	0.17	60	63	36.47	36.30	-	55.2	37.9	6.9	LDA	
7	4	5	0.08	42	14	14.68	14.60	3.2	25.8	71.0	-	MDA	MDA
8	5	8	0.35	13	66	21.25	20.90	3.2	9.7	61.3	25.8	MDA	
9	6	8	0.32	47	47	23.72	23.40	3.3	10.0	60.0	26.7	MDA	
10	2	9	0.27	48	62	22.27	22.00	-	38.7	58.1	3.2	MDA	
11	1	5	0.08	66	55	18.18	18.10	-	70.0	30.0	-	LDA	
12	2	8	0.18	51	100	25.28	25.10	-	27.6	65.5	6.9	MDA	
13	0	0	0.11	25	70	9.61	9.50	56.7	40.0	3.3	-	REM	LDA
14	0	0	1.97	35	46	10.07	8.10	23.3	73.3	3.3	-	LDA	
15	0	2	0.60	19	15	6.00	5.40	25.8	74.2	-	-	LDA	
16	3	3	0.10	34	32	12.70	12.60	-	51.6	48.4	-	LDA	
17	1	2	0.37	32	5	7.07	6.70	9.7	90.3	-	-	LDA	
18	2	1	0.57	9	21	6.57	6.00	3.4	79.3	17.2	-	LDA	
19	2	1	0.39	2	5	4.09	3.70	10.0	83.3	6.7	-	LDA	
20	0	1	0.17	25	5	4.17	4.00	75.9	24.1	-	-	REM	
21	1	2	0.41	36	32	10.21	9.80	10.7	89.3	-	-	LDA	
22	1	0	5.88	27	28	12.38	6.50	3.3	76.7	20.0	-	LDA	
23	0	0	0.11	0	17	1.81	1.70	96.7	3.3	-	-	REM	REM
24	1	1	0.20	7	7	3.60	3.40	43.3	56.7	-	-	LDA	

25	0	0	1.74	4	6	2.74	1.00	73.3	26.7	-	-	REM
26	0	0	0.30	0	23	2.60	2.30	92.9	7.1	-	-	REM
27	1	0	0.34	7	7	2.74	2.40	34.5	65.5	-	-	LDA
28	0	1	0.82	0	0	1.82	1.00	82.8	17.2	-	-	REM
29	0	0	0.27	3	4	0.97	0.70	100	-	-	-	REM
30	0	1	1.02	6	12	3.82	2.80	60.7	39.3	-	-	REM

Table S1. Individual disease activity parameters and compound scores of 30 patients in our survey, and the respective disease activity classification by experts in percent. Majority rating: Classification according to >50% of experts. Percentile rating: Classification according to percentiles (main analysis with 25th and 75th percentiles of DAPSA); ID=Patient Identification number; SJC66=swollen joint count; TJC68=tender joint count; CRP=C-reactive protein; PP=patient pain rating; PtGA=patient global assessment; DAPSA=disease activity for psoriatic arthritis; cDAPSA=clinical DAPSA; REM=remission; LDA=low disease activity; MDA=moderate disease activity; HDA =high disease activity.

Supplementary Table S2.

	F U	total n	PsARC		EULAR good		EULAR moderate		EULAR non		ACR20		ACR50		ACR70		DAS REM		SDAI REM		CDAI REM		Boolean REM	
			n	%	n	%	N	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
DAPSA 50%	3	213	186	90.3	161	75.6	48	22.5	4	1.9	154	72.3	109	51.2	56	26.3	126	59.2	56	26.8	53	25.4	50	23.5
	6	244	217	91.2	177	72.5	58	23.8	9	3.7	170	69.7	126	51.6	78	32.0	149	61.1	89	36.9	82	34.0	71	29.1
DAPSA 75%	3	114	105	94.6	108	94.7	6	5.3	2	1.4	92	80.7	85	74.6	53	46.5	97	85.1	54	48.6	51	45.9	50	43.9
	6	138	132	99.2	129	93.5	7	5.1	1	1.1	107	77.5	99	71.7	72	52.2	115	83.3	83	61.5	77	57.0	68	49.3
DAPSA 85%	3	67	63	96.9	63	94.0	4	6.0	1	1.8	53	79.1	53	79.1	43	64.2	62	92.5	44	67.7	43	66.2	45	67.2
	6	91	85	98.8	90	98.9	3	5.3	3	3.9	74	81.3	71	78.0	61	67.0	86	94.5	67	76.1	63	71.6	60	65.9
DAPSA REM	3	59	50	96.2	53	93.0	1	1.3	8	7.2	40	67.8	40	67.8	31	52.5	59	100	49	87.5	48	85.7	47	79.7
	6	77	69	98.6	72	94.7	13	11.7	6	5.2	56	72.7	54	70.1	47	61.0	77	100	68	91.9	64	86.5	62	80.5
DAPSA LDA	3	113	88	81.5	90	81.1	16	13.9	21	21.2	78	69.0	59	52.2	25	22.1	73	64.6	12	10.7	10	8.93	9	8.0
	6	117	101	90.2	93	80.9	46	46.5	19	18.8	79	67.5	56	47.9	29	24.8	75	64.1	25	21.4	22	18.8	12	10.3
DAPSA MDA	3	101	56	57.7	32	32.3	55	54.5	77	55.8	38	37.6	12	11.9	1	1.0	12	11.9	1	1.0	1	1.0	2	1.9
	6	104	54	52.9	27	26.7	59	42.8	61	53.5	42	40.4	16	15.4	3	2.9	14	13.5	1	1.0	-	-	-	-
DAPSA HDA	3	141	46	33.1	2	1.4	51	44.7	-	-	30	21.3	5	3.5	-	-	-	-	-	-	-	-	-	-
	6	117	40	34.8	2	1.8	-	-	-	-	27	23.1	5	4.3	-	-	-	-	-	-	-	-	-	-

Table S2. Patients who achieved DAPSA 50/75/85 response after 3 months and after 6 months follow-up (FU), who also classify as PsARC-response, EULAR good or moderate response, ACR20/50/70 and / or DAS-, SDAI-, CDAI- and / or Boolean remission. Included are patients in ADEPT, IMPACT and GO-REVEAL (pooled results of patients in treatment arms); PsARC=Psoriatic Arthritis Response Criteria; DAS=Disease Activity Score using 28 joint counts; ACR20/50/70= American College for Rheumatology (ACR) Response Criteria; DAPSA=Disease Activity Index for Psoriatic Arthritis; REM=remission; LDA=low disease activity; MDA=moderate disease activity; HDA=high disease activity; FU=follow-up in months.

Supplementary Table S3.

Follow-up	Response Criteria	χ^2	p
3 months	ACR20	39.86	<0.0001
	ACR50	26.74	<0.0001
	ACR70	19.46	<0.0001
	DAPSA50	52.73	<0.0001
	DAPSA75	37.53	<0.0001
	DAPSA85	14.82	0.0001
	EULAR	20.15	<0.0001
	PsARC	37.07	<0.0001
6 months	ACR20	32.51	<0.0001
	ACR50	30.19	<0.0001
	ACR70	18.65	<0.0001
	DAPSA50	41.68	<0.0001
	DAPSA75	30.47	<0.0001
	DAPSA85	26.79	<0.0001
	EULAR	21.20	<0.0001
	PsARC	39.67	<0.0001

Table S3. Chi-Square analysis of different response criteria for the comparison of adalimumab and placebo in the ADEPT trial. X=Chi; p=level of significance; ACR20/50/70=American College of Rheumatology response (borrowed from RA); DAPSA50/75/85=Disease Activity Index for Psoriatic Arthritis 50%, 75% and 85% response; EULAR=European League Against Rheumatism response criteria (borrowed from RA); PsARC=Psoriatic Arthritis Response Criteria.

Supplementary Table S4.

Trial	Treatment Arm	State	Baseline		3 Months Follow-up		6 Months Follow-up	
			n	%	n	%	n	%
ADEPT	Adalimumab	REM	-	-	21	17.1	30	23.8
		LDA	4	3.2	35	28.5	31	24.6
		MDA	28	22.2	27	22.0	30	23.8
		HDA	94	74.6	40	32.5	35	27.8
	Placebo	REM	-	-	1	0.7	4	2.9
		LDA	4	3.0	14	10.3	13	9.6
		MDA	26	19.3	33	24.3	33	24.3
		HDA	105	77.8	88	64.7	86	63.2
GO-REVEAL	Golimumab 100mg + Placebo	REM	-	-	14	11.4	18	14.8
		LDA	4	3.3	36	29.3	42	34.4
		MDA	20	16.4	31	25.2	23	18.9
		HDA	98	80.3	42	34.2	39	32.0
	Golimumab 50mg + Methotrexate	REM	-	-	18	14.3	20	15.8
		LDA	1	0.8	30	23.8	31	24.4
		MDA	31	24.4	28	22.2	39	30.7
		HDA	95	74.8	50	39.7	37	29.1
IMPACT	Infliximab	REM	-	-	6	14.3	9	22.5
		LDA	-	-	13	31.0	13	32.5
		MDA	8	20.5	14	33.3	12	30.0
		HDA	31	79.5	9	21.4	6	15.0
	Placebo	REM	-	-	-	-	6	16.2
		LDA	-	-	1	2.9	16	43.2
		MDA	8	24.2	6	17.7	9	24.3
		HDA	25	75.8	27	79.4	6	16.2

Table S4. DAPSA disease activity states in the ADEPT, GO-REVEAL and IMPACT trials at baseline and after 3 and 6 months follow-up. Numbers of patients in each state (n) and percentage (%) are specified. REM=remission; LDA=low disease activity; MDA=moderate disease activity; HDA=high disease activity.